Pharmacotherapies for Cannabis Use Disorders: Clinical Challenges and Promising Therapeutic Agents.

Abstract

This chapter reviews pharmacotherapies that have been trialled for cannabis dependence, identifying those that warrant further research and those of little or uncertain value. A diverse range of medicines have been tested, representing a broad range of pharmacological strategies. These include tetrahydrocannabinol preparations, various types of antidepressant, anxiolytics, a glutamatergic modulator and the neuropeptide oxytocin. Cannabinoid agonists warrant further research. For the FAAH inhibitor PF-04457845, oxytocin, varenicline and gabapentin, although there is a signal to indicate further research is warranted, these medications do not yet have sufficient evidence to support clinical use, and larger, longer-term trials are needed in representative treatment-seeking populations. Special populations that warrant consideration are those with cannabis dependence and concurrent mental health conditions and those that develop dependence through therapeutic use.

• Authors: Suzanne Nielsen, Pamela Sabioni, Linda Gowing, Bernard Le Foll
• Journal: Handbook of experimental pharmacology (Handb Exp Pharmacol) Vol. 258 Pg. 355-372 ( 2020) ISSN: 0171-2004 [Print] Germany
• PMID: 31375922 (Publication Type: Journal Article, Review)

Chemical References

• Cannabinoid Receptor Agonists
• Dronabinol

Topics

• Cannabinoid Receptor Agonists (pharmacology)
• Cannabis
• Dronabinol
• Humans
• Marijuana Abuse (drug therapy)